PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32965028-11	2021	In the scope of the registration of PARP inhibitors (PARPi) for mCRPC, we provide initial insights on cross-resistance between PARPi and platinum compounds.	Platinum	137-145	collagen type XI alpha 2 chain	Homo sapiens	36-40	
32709856-0	2020	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.	Platinum	64-72	collagen type XI alpha 2 chain	Homo sapiens	10-14	
32833070-5	2020	RESULTS: Most notably, patients with BRCA1/2 mutant ovarian cancer benefit from maintenance treatment with PARP inhibitors after (complete or partial) response to platinum-based chemotherapy.	Platinum	163-171	collagen type XI alpha 2 chain	Homo sapiens	107-111	
32948057-2	2020	Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-mutated PDAC patients after platinum-based induction for the first time.	Platinum	158-166	collagen type XI alpha 2 chain	Homo sapiens	44-48	
28454085-3	2017	Although platinum sensitivity has been suggested as a marker of response to PARP inhibitors, patients with platinum-resistant disease still respond to olaparib.	Platinum	9-17	collagen type XI alpha 2 chain	Homo sapiens	76-80	
31787750-1	2020	Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi).	Platinum	207-215	collagen type XI alpha 2 chain	Homo sapiens	264-268	
31857852-3	2019	The FDA has approved the PARP inhibitor olaparib (Lynparza ) as maintenance treatment after first-line platinum-containing chemotherapy and olaparib, niraparib (Zejula ) and rucaparib (Rubraca ) are approved as maintenance therapies in the recurrent, platinum-sensitive setting; nevertheless, development of resistance limits their efficacy.	Platinum	251-259	collagen type XI alpha 2 chain	Homo sapiens	25-29	
30940721-1	2019	In an interim analysis, the targeted PARP inhibitor rucaparib showed encouraging signs of disease control when used as a maintenance therapy for patients with platinum-sensitive advanced pancreatic cancer and a pathogenic mutation in BRCA1, BRCA2, or PALB2.	Platinum	159-167	collagen type XI alpha 2 chain	Homo sapiens	37-41	
31653094-1	2019	The PARP inhibitor olaparib has been approved in the maintenance setting of platinum-sensitive epithelial ovarian cancer patients with germline or somatic BRCA1/2 mutation.	Platinum	76-84	collagen type XI alpha 2 chain	Homo sapiens	4-8	
28454085-10	2017	CONCLUSION: PTPI may be used to refine the prediction of response to PARP inhibition based on the conventional categorization of platinum sensitivity.	Platinum	129-137	collagen type XI alpha 2 chain	Homo sapiens	69-73	
26210103-5	2015	In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are present in both somatic and germline form in a significant minority of prostate cancer; these abnormalities can be targeted by drugs such as platinums and PARP inhibitors.	Platinum	241-250	collagen type XI alpha 2 chain	Homo sapiens	255-259	
27617661-1	2016	BACKGROUND: In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo.	Platinum	29-37	collagen type XI alpha 2 chain	Homo sapiens	114-118	
23922302-1	2013	PURPOSE: Preclinical data suggest that exposure to PARP inhibitors (PARPi) may compromise benefit to subsequent chemotherapy, particularly platinum-based regimens, in patients with BRCA1/2 mutation carrier ovarian cancer (PBMCOC), possibly through the acquisition of secondary BRCA1/2 mutations.	Platinum	139-147	collagen type XI alpha 2 chain	Homo sapiens	51-55	
26303225-0	2015	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.	Platinum	53-61	collagen type XI alpha 2 chain	Homo sapiens	0-4	
35164068-4	2022	To discover compounds capable of restoring platinum sensitivity, we screened a number of candidates and monitored ability to induce PARP cleavage.	Platinum	43-51	collagen type XI alpha 2 chain	Homo sapiens	132-136	
23666017-1	2013	OBJECTIVES: (1) To determine whether use of a PARP inhibitor or (2) BRCA1/2 mutation testing followed by a PARP inhibitor for test positives is potentially cost-effective for maintenance treatment of platinum-sensitive recurrent high-grade serous ovarian cancer.	Platinum	200-208	collagen type XI alpha 2 chain	Homo sapiens	107-111	
34293664-1	2021	BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely.	Platinum	146-154	collagen type XI alpha 2 chain	Homo sapiens	51-55	
20060649-9	2010	The aim of this review, that focuses on triple-negative breast cancer, is to summarize the most relevant knowledge on this particular type of cancer in terms of molecular features, pathogenesis, clinical characteristics, current treatments and the new therapeutic options that include the use of platinum compounds, EGFR antagonists, antiangiogenics and PARP inhibitors.	Platinum	296-304	collagen type XI alpha 2 chain	Homo sapiens	354-358	
35425960-1	2022	PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR).	Platinum	47-55	collagen type XI alpha 2 chain	Homo sapiens	0-4